2024 saw the completion of several cellular-resolution brain maps, including the entire fly brain and a comprehensive connections map of a cubic centimeter of human brain. 2025 began with the addition of another important map. In the Jan. 1, 2025, issue of Nature, researchers from the Allen Institute presented a map of areas and cell types where aging most affected the mouse brain. Read More
Researchers from Gedeon Richter plc have reported the discovery of novel dual vasopressin V1A/V2 antagonist drug candidates for the potential treatment of hyponatremia. Read More
Cyrus Biotechnology Inc. has selected CYR-212, an engineered next-generation reduced-immunogenicity and half-life extended immunoglobulin G (IgG) protease, as a clinical development candidate for chronic IgG-driven autoimmune disease. Read More
Celmatix Therapeutics (Celmatix Inc.) has announced a new drug program for endometriosis, with the development of a novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation. The company’s aim to focus on JNK inhibitors with greater specificity for JNK1 and JNK3 than for JNK2 led it to license lead compounds from Baylor College of Medicine. Read More
Fauna Bio Inc. has nominated Faun-1083 as its first development candidate, for the treatment of heart failure with preserved ejection fraction (HFpEF). Faun-1083 is a novel small-molecule therapeutic that has demonstrated promising in vivo efficacy in multiple preclinical animal models. Read More
Haisco Pharmaceutical Group Co. Ltd. has disclosed quinazolinone derivatives acting as poly(ADP-ribose) polymerase 14 (PARP-14; ARTD8) inhibitors reported to be useful for the treatment of cancer, atopic dermatitis and autoimmune disease. Read More
Alesta Therapeutics BV has closed an oversubscribed €65 million (US$67 million) series A financing round designed to support development of its two small-molecule therapeutics. Read More
The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases. Read More
Researchers at Leiden University Medical Center and Universiteit Leiden have synthesized anthracyclins reported to be useful for the treatment of cancer. Read More
Quanta Therapeutics Inc. has gained IND clearance from the FDA for QTX-3544, an oral multi-KRAS inhibitor with G12V-preferring activity and dual ON/OFF state. Read More
Chengdu Zeling Biomedical Technology Co. Ltd. has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders. Read More
Transneural Therapeutics Inc. has described 5-HT2A receptor modulators reported to be useful for the treatment of depression, anxiety, substance abuse and dependence, and headache. Read More
Oral squamous cell carcinoma (OSCC), a major subset of head and neck cancers, is known for its high mortality rates and limited treatment options. Read More
